Lesaka Technologies (LSAK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Jul, 2026Executive summary
Special Meeting of Shareholders scheduled for August 3, 2026, to approve a share option grant to Executive Chairman Ali Mazanderani in compliance with Nasdaq Listing Rule 5635(c).
The Option Award allows Mr. Mazanderani to purchase 1,000,000 shares at $5.00 per share, vesting on April 1, 2028, and exercisable after April 1, 2029, if he remains employed through the vesting date.
The Board believes the award aligns Mr. Mazanderani’s interests with shareholders and incentivizes long-term performance.
If shareholders do not approve the grant, the option will be forfeited.
Voting matters and shareholder proposals
Only one proposal is up for vote: approval of the share option grant to Mr. Mazanderani.
Approval requires more votes in favor than against; abstentions and broker non-votes do not affect the outcome.
Shareholders of record as of June 15, 2026, are eligible to vote; special instructions apply for South African shareholders.
Shareholder proposals and director nominations for the 2026 annual meeting must be submitted by June 29, 2026.
Board of directors and corporate governance
The Board unanimously recommends voting FOR the share option agreement proposal.
The Option Award will be administered by the Board or its remuneration committee, with authority to interpret and apply the agreement.
Latest events from Lesaka Technologies
- FY2027 guidance reaffirmed amid Consumer and Enterprise growth and Merchant weakness.LSAK
Q1 2027 - The board recommends For on 11 director nominees, auditor ratification, and say-on-pay.LSAK
Proxy filing - Three shareholder votes anchor a proxy focused on board oversight and performance-linked executive pay.LSAK
Proxy filing - FY2026 delivered strong growth, GAAP profitability, and progress on the Bank Zero acquisition.LSAK
Q4 2026 - Integrated fintech platform in Southern Africa delivers strong growth and expands through strategic acquisitions.LSAK
Corporate presentation - Vote sought on a major share option grant to the Executive Chairman, with long-term vesting.LSAK
Proxy filing - Q3 FY2026 saw 16% revenue growth, 45% EBITDA rise, and a raised full-year outlook.LSAK
Q3 2026 - Revenue up 7% to $145.5M, EBITDA up 12%, and Adumo acquisition expands scale.LSAK
Q1 2025 - Record net revenue and EBITDA growth in ZAR, with major acquisitions and debt refinancing completed.LSAK
Q3 2025